Last reviewed · How we verify
Clopidogrel only
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke.
At a glance
| Generic name | Clopidogrel only |
|---|---|
| Sponsor | Seung-Jung Park |
| Drug class | P2Y12 receptor antagonist / Thienopyridine antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form. The active metabolite binds irreversibly to the P2Y12 receptor on platelet surfaces, blocking adenosine diphosphate (ADP)-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients at risk of cardiovascular complications.
Approved indications
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke
Common side effects
- Bleeding
- Rash
- Gastrointestinal bleeding
- Thrombotic thrombocytopenic purpura (TTP)
- Neutropenia
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel only CI brief — competitive landscape report
- Clopidogrel only updates RSS · CI watch RSS
- Seung-Jung Park portfolio CI